NanoenTekInc (039860) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NanoenTekInc (039860) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.26 Billion ≈ $1.53 Million USD) by net assets (₩73.19 Billion ≈ $49.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NanoenTekInc stock valuation for the company's overall valuation and market capitalisation.
NanoenTekInc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how NanoenTekInc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
NanoenTekInc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NanoenTekInc ranked by their cash flow conversion efficiency. Explore 039860 cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DeviceENG.CO.Ltd
KQ:187870
|
0.035x |
|
Agrify Corp
NASDAQ:AGFY
|
-0.459x |
|
Hf Foods Group Inc
NASDAQ:HFFG
|
-0.006x |
|
ÖKOWORLD AG
XETRA:VVV3
|
0.008x |
|
Fast Ejendom
CO:FED
|
0.010x |
|
Dongyang E&P Inc
KQ:079960
|
-0.017x |
|
Tradetool Auto Co Ltd
TWO:3685
|
0.040x |
|
FELIX Gold Ltd
AU:FXG
|
-0.022x |
Annual Cash Flow Conversion Efficiency for NanoenTekInc (2013–2024)
The table below shows the annual cash flow conversion efficiency of NanoenTekInc from 2013 to 2024. View 039860 live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩73.99 Billion ≈ $50.15 Million |
₩-2.46 Billion ≈ $-1.67 Million |
-0.033x | -175.79% |
| 2023-12-31 | ₩53.59 Billion ≈ $36.32 Million |
₩-645.79 Million ≈ $-437.64K |
-0.012x | -108.64% |
| 2022-12-31 | ₩57.65 Billion ≈ $39.07 Million |
₩8.04 Billion ≈ $5.45 Million |
0.140x | -21.38% |
| 2021-12-31 | ₩52.34 Billion ≈ $35.47 Million |
₩9.29 Billion ≈ $6.30 Million |
0.177x | +41.71% |
| 2020-12-31 | ₩45.49 Billion ≈ $30.83 Million |
₩5.70 Billion ≈ $3.86 Million |
0.125x | +25.86% |
| 2019-12-31 | ₩41.03 Billion ≈ $27.80 Million |
₩4.08 Billion ≈ $2.77 Million |
0.100x | +131.90% |
| 2018-12-31 | ₩35.15 Billion ≈ $23.82 Million |
₩1.51 Billion ≈ $1.02 Million |
0.043x | -40.33% |
| 2017-12-31 | ₩23.73 Billion ≈ $16.08 Million |
₩1.71 Billion ≈ $1.16 Million |
0.072x | +160.86% |
| 2016-12-31 | ₩25.58 Billion ≈ $17.33 Million |
₩-3.02 Billion ≈ $-2.05 Million |
-0.118x | -28.30% |
| 2015-12-31 | ₩38.41 Billion ≈ $26.03 Million |
₩-3.54 Billion ≈ $-2.40 Million |
-0.092x | -100.69% |
| 2014-12-31 | ₩35.50 Billion ≈ $24.06 Million |
₩-1.63 Billion ≈ $-1.10 Million |
-0.046x | -152.33% |
| 2013-12-31 | ₩23.58 Billion ≈ $15.98 Million |
₩2.07 Billion ≈ $1.40 Million |
0.088x | -- |
About NanoenTekInc
NanoEntek, Inc. engages in the research and development, production, and sale of life-science lab equipment, in vitro diagnostic medical devices, point of care diagnostic devices, and related consumables and solutions in Korea and internationally. It provides FREND system, a fluorescence immunoassay analyzer; BUDDI, a rapid diagnostic test analyzer; rapid diagnostic test items; ADAM-rWBC, a resid… Read more